Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Japan Medical Dynamic Marketing Inc Lowers Consolidated Full-year Outlook for FY 2013
Japan Medical Dynamic Marketing Inc announced that it has lowered its consolidated full-year outlook for revenue from JPY 9,500 million to JPY 8,340 million, operating profit from JPY 700 million to JPY 50 million, ordinary profit from JPY 550 million to a loss of JPY 140 million, net profit from JPY 260 million to a loss of JPY 210 million and earning per share from JPY 9.83 to a loss of JPY 7.94, for the fiscal year ending March 2013. The Company lowered the outlook due to the decreased sales, among others.
Latest Developments for Japan Medical Dynamic Marketing Inc
- Japan Medical Dynamic Marketing Inc Raises Consolidated Full-year Outlook for FY 2013
- Japan Medical Dynamic Marketing Inc Receives Approval of New Pharmaceutical Product in China Market
- Japan Medical Dynamic Marketing Inc Receives Approval of New Pharmaceutical Product
- Japan Medical Dynamic Marketing, Inc. Receives Approval of New Pharmaceutical Product
Latest Key Developments in Medical
- CryoLife Inc Receives Conditional IDE Approval To Begin Clinical Trials For PerClot In The U.S.
- Essilor International SA Acquires Eight Businesses
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Share this
- Link this
- Digg this
Follow Reuters